Ezogabine

Generic Name: Ezogabine

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₈FN_₃O_₂

CAS Number: 150812-12-7

Unique Ingredient Identifier: 12G01I6BBU

Overview

Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.

Background

Indication

Adjuvant treatment of partial-onset seizures.

Associated Conditions

Refractory Partial Onset Seizures

Epilepsy Drug Ezogabine Shows Promise as Novel Depression Treatment by Targeting Brain Potassium Channels

2 months ago

Two recent studies reveal that ezogabine, an FDA-approved epilepsy medication, may effectively treat depression by normalizing hyperactivity in the brain's reward circuitry through KCNQ potassium channel modulation.

QurAlis Reports Promising Phase 1 Data for QRL-101 in ALS and Epilepsy Biomarker Study

2 months ago

QRL-101 demonstrated a dose-dependent, statistically significant decrease in SDTC, a biomarker linked to ALS disease progression and mortality, with effects approximately 50% greater than the previous Kv7 opener ezogabine.

Douglas Tsao Maintains Buy Rating on Xenon Pharmaceuticals' Azetukalner

5 months ago

Douglas Tsao of H.C. Wainwright reaffirms a Buy rating for Xenon Pharmaceuticals, citing the promising efficacy and tolerability of its antiepileptic drug, azetukalner, supported by positive trial results and its impact on patients' emotional well-being.

Biohaven's BHV-7000 Shows Promising Safety and Efficacy Profile for Epilepsy Treatment

6 months ago

Biohaven's BHV-7000 demonstrates excellent tolerability in Phase 1 trials, with no CNS adverse effects typically associated with anti-seizure medications.

Drug Development Updates